Brief: Novartis AG Says Acquisition Of Avidity Valued At $12 Billion

Avidity Biosciences

26/10/2025 17:03

Oct 26 (Reuters) - Novartis AG NOVN.S:

NOVARTIS AGREES TO ACQUIRE AVIDITY BIOSCIENCES, AN INNOVATOR IN RNA THERAPEUTICS, STRENGTHENING ITS LATE-STAGE NEUROSCIENCE PIPELINE

NOVARTIS AG - ACQUISITION OF AVIDITY VALUED AT $12 BILLION

NOVARTIS AG - AVIDITY STOCKHOLDERS TO RECEIVE $72 PER SHARE, 46% PREMIUM

NOVARTIS AG - RAISES EXPECTED SALES CAGR TO 6% FOR 2024-2029

NOVARTIS AG -AVIDITY WILL SEPARATE ITS EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO A NEW COMPANY ("SPINCO") PRIOR TO CLOSING

NOVARTIS AG -NOVARTIS AG - ACQUISITION OF AVIDITY VALUED AT $12 BILLION

Source text: ID:nGNE9nCGzq

Further company coverage: NOVN.S

 ((Reuters.Briefs@thomsonreuters.com;))